Gary Von Burton, M.D.

Contact

Phone: (318) 675-5972
Clinic Phone: (318) 813-1200
Fax: (318) 675-4338
GBurto@lsuhsc.edu

Team Membership

Breast Cancer
Brain Cancer
Sarcoma/Bone Cancer

Hereditary Cancer Risk Assessment Program

Professor of Medicine, Section of Hematology-Oncology, Department of Medicine, LSU Health Science Center, Shreveport Director of Inpatient and Outpatient clinical Oncology Units, LSU Health Science Center, Shreveport, Louisiana.

Co-Director of Multidisciplinary Breast Sarcoma and Brain Tumor Programs, LSU Health Science Center.

Clinical Services / Education / Honors / Board Certifications / Professional Associations / Research / Publications

Clinical Services

Professor of Medicine, Section of Hematology-Oncology, Department of Medicine, LSU Health Science Center, Shreveport
Director of Inpatient and Outpatient clinical Oncology Units, LSU Health Science Center, Shreveport, Louisiana.
Co-Director of Multidisciplinary Breast Sarcoma and Brain Tumor Programs, LSU Health Science Center.

Education / Professional Experience

Weber State College, Ogden, Utah, B.S., 1974

University of Utah College of Medicine, Salt Lake City, Utah, M.D., 1978

Resident in Medicine, Duke University Medical Center, Durham, North Carolina, 1978-1981

Fellow in Hematology/Oncology, Duke University Medical Center, Durham, North Carolina, 1981-1983

Associate in Medicine, July, 1983 – January 1986.
Assistant Professor of Medicine, January, 1986 – June, 1987.
Clinical Associate in Medicine, NC, July, 1987 – June, 1992.
Duke University Medical Center, Durham, NC

Assistant Professor of Medicine October 1986 – June 1991.
Associate Professor of Medicine July 1991 – July 2000.
Professor of Medicine July 2000 – present.
Louisiana State University Health Science Center – Shreveport, Shreveport, LA

Honors and Awards

Phi Kappa Phi National Honor Society, Weber State College
Student Research Award, University of Utah College of Medicine
Western Student Medical Research Forum Research Award
James A. Busch Memorial Research Award, University of Utah College of Medicine
Alpha Omega Alpha Honor Society
LSUHSC-Shreveport: Alan Copping Teaching Award 2001.
LSUHSC-Shreveport: Humanism in Medicine Award 2003.

Fellowship

Fellow in Hematology/Oncology, Duke University Medical Center, Durham, North Carolina, 1981-1983

Board Certifications

American Board of Internal Medicine
American Board of Medical Oncology
American Board of Hematology

Professional Associations

American Society of Clinical Oncology
American Association for Cancer Research
Southwest Oncology Group
Developmental Therapeutics Committee
Sarcoma Committee
Breast Committee
GI Committee
Brain Committee
Head and Neck Committee
NSABP Cooperative Oncology Group (Institutional Principle Investigator)
The American Federation for Clinical Research

Selected Publications

Journal articles

  1. Burton GV, Alley RJ, Rasmussen GL, Cox V, Jones P, Orton P, Graff DJ.  Levels and effects of mercury in northern Utah.  In National Science Foundation SOS Reports.  Berton F. Hill (ed.), National Science Foundation, Washington, D.C.  1974.
  2. Burton GV, Alley RJ, Rasmussen GL, Cox V, Jones P, Orton P, Graff DJ.  Mercury and behavior in wild mouse populations.  Environ Res  14:30-34, 1977.
  3. Meikle AW, Burton GV, Stringham JD, Fang SM.  Content of 5 alpha-reduced androgens in subcellular compartments of dog prostate.  J Steroid Biochem 11:1503-5, 1979.
  4. Burton GV, Miekle AW.  Acute and chronic methylmercury poisoning impairs rat adrenal and testicular function.  J Toxicol Enviro Health  6:597-606, 1980.
  5. Halvorsen RA Jr, Heaston K, Johnston WW, Ashton PA. and Burton GV.   CT guided thin needle aspiration of adrenal blastomycosis.  J Comp Ass Tomo  6:389-391, 1982.
  6. Burton GV, Weinberg JB, Borowitz MJ.   Extramedullary recurrence of acute lymphoblastic leukemia 15 years after initial diagnosis.  Med Pediatr Onc  12:255-257, 1984.
  7. Flowers JL, Burton GV, Cox EB, Duet GA, Geissenger KR, McCarty KS.  Use of monoclonal anti-estrogen receptor antibody to evaluate estrogen receptor content in fine needle aspiration breast biopsies.  Annals Surg  203:250-254, 1986.
  8. Fisher SR, Burton GV, Murray JC, Borowitz M, Crocker IR.  Primary cutaneous lymphoma of the head and neck region.  Laryngoscope.  96:653-655, 1986.
  9. Wolfe W, Burton G, Seigler H, Crocker I, Vaughn A.   Multimodality therapy of esophageal carcinoma.  Annals Surg.  205:563-571, 1987.
  10. Burton GV, Cox EB, Leight GS, Prosnitz LR, Inglehart JD, Olsen GA, Seigler, HF, Hart LL.  Inflammatory breast carcinoma: Effective multimodality approach with short-term chemotherapy, surgery, and radiation therapy.  Archives of Surg. 122:1329-1332, 1987.
  11. Burton GV, Flowers JL, Cox EB, Leight GS, Dent GA, Geissinger KR, McCarty KS, McCarty KS Jr.  Estrogen receptor determination by monoclonal antibody in fine needle aspiration breast cancer cytologies:  A marker of hormone response.  Breast Cancer Res Treat 10:287-291, 1987.
  12. Burton GV, Bullard DE, Walther PJ, Burger PC.  Paraneoplastic limbic encephalopathy with testicular carcinoma: A reversible neurologic syndrome.  Cancer 62:2248-2251, 1988.
  13. Burton GV.  Multidisciplinary approaches to the management of locally advanced and inflammatory breast carcinoma.  Schumpert Medical Quarterly 7:170-178, 1988.
  14. Green DM, Burton GV, Cox EB, Hanson D, Moore J, Oleson JR.  A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy.  Int J Hyperthermia 5:13-21, 1989.
  15. Cox E, Burton G, Olsen GA, Vugrin D.  Cisplatinum and Etoposide:  An effective treatment for refractory breast cancer.  Amer J Clin Oncol (CCT) 12:53-56, 1989.
  16. Burton GV, Hart LL, Leight GS, Iglehart JD, McCarty KS Jr, Cox EB.  Cystosarcoma Phyllodes: Effective therapy with cisplatin and etoposide chemotherapy.  Cancer 63:2088-2092, 1989.
  17. Berglund E, Burton GV, Mills G, Nichols G.  Hypertrichosis of the eyelashes with alpha interferon therapy of chronic myelogenous leukemia.  Southern Medical Journal 83:363, 1990.
  18. Burton GV, Atwater S, Borowitz MJ, Huang AW.  Extranodal head and neck lymphomas:  Prognosis and patterns of recurrence.  Arch Otolaryngol Head Neck Surg 116:69-73, 1990.
  19. Tucker JD, Wyrobek AJ, Ashworth LK, Christensen ML, Burton GV, Carrano AV, Everson RB.  Induction, accumulation, and persistence of sister chromatid exchanges in women with breast cancer receiving cyclophosphamide, adriamycin, and 5-fluorouracil chemotherapy.  Cancer Research 50:4951-6.1990.
  20. Bordelon TR, Burton GV, Grafton WD, Mills GM.  Kaposi’s sarcoma involvement of the bone marrow.  Am J Med Sci 300:383-384, 1990.
  21. Burton GV, Wolfe WG, Crocker I, Seigler HF, Prosnitz LR, Crawford J.  Adenocarcinoma of the gatroesophageal junction:  preoperative cisplatin and concomitant continuous infusion 5-fluorouracil and radiation therapy.  In Rotman and Rosenthal (eds): Medical Radiology:  Concomitant Continuous Infusion Chemotherapy and Radiation.   Springer-Verlag, Berlin 1991.
  22. Rush BM, Hood JS, McDonald JC, Grafton WD, Burton GV.  Retroperitoneal necrotizing fasciitis.  J La State Med Soc 143:23-4, 1991.
  23. Blanchet P, Wellemyer ML, Burton GV.  Retinitis pigmentosa following cytotoxic chemotherapy in Usher’s syndrome.  Amer J Med Sciences 303:319-320,1992.
  24. Bounds WE, Burton GV, Schwalke MA.  Male breast cancer.  J La State Med Soc 145:353-356, 1993.
  25. Ampil FL, Burton GV, Hardjasudarma M, Stogner SW.  Chylous effusion complicating chronic lymphocytic leukemia.  Leuk Lymph 10:507-510, 1993.
  26. Ampil FL, Burton GV, Chin HW, Hardjasudarma M.  Radiotherapy for mediastinal obstruction and intrathoracic lymphadenopathy in chronic lymphocytic leukemia.  Radiation Medicine 11:206-209, 1993.
  27. Campbell LC, Von Burton GV, Holcomb RF.  Transfusion therapy in sickle cell disease patients: methods and acute indications.  J La State Med Soc 145:: 515-521, 1993.
  28. Cubeddu LX, Pendergrass K, Ryan T, York M, Burton G, Meshad M, Galvin D, Ciociola AA.  Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy.  Amer J Clin Oncol 17:137-146, 1994.
  29. Ampil FL, Burton GV, Mills GM, Hollenberg HG.  Long-term survival in small cell lung cancer with superior vena caval obstruction,  J La State Med Soc 146:384-388, 1994.
  30. Ampil FL, Mills GM, Burton GV, Abreo F.  Solitary plasmacytoma of the sacrum presenting as pelvic mass:  Report of two cases.  Southern Medical Journal 88:494-496, 1995.
  31. Hochberg F, Prados M, Russell C, Weissman D, Evans R, Cook P, Burton G, Eisenberg P, Verkh L, Valenzuela R.  Treatment of recurrent malignant glioma with BCNU-Fluosol and oxygen inhalation. A phase I-II study.  J Neurooncol 32:45-55, 1997.
  32. Cain MS, Burton GV, Holcombe RF.  Fatal leukoencephalopathy in a patient with non-Hodgkin’s lymphoma treated with CHOP chemotherapy and high-dose steroids.  Southern Medical Journal 315:202-207, 1998.
  33. Ampil FL, Burton GV, Abreo A, Apple S, Hardjasudarma M.  Small cell cancer of the cervix presenting as compression of the spinal cord and cauda equina.  Southern Medical Journal 91:293-295, 1998.
  34. Johnson D, Hayat S, Burton GV.  Rheumatiod arthritis complicating adjuvant alpha-interferon therapy for malignant melanoma.  J Rhematology 26:1009-1010, 1999.
  35. Ampil FL, Mills GM, Burton GV.  Induction chemotherapy followed by concomitant chemoradiation for cervical esophageal cancer.  Amer J Gastro 94:12-13, 1999.
  36. Ampil FL, Mills GM, Burton GV, Heldman M.  Multiple myeloma metastatic to the thigh: successful treatment with radiation therapy.  J La Stae Med Soc 151:136-7, 1999.
  37. Ampil FL, Mills GM, Burton GV.  Radiotherapy with and without chemotherapy after breast conservation surgery for early stage breast cancer: a review of timing.  Eur J Gynaec Oncol 20:254-257, 1999.
  38. Ampil FL, Burton GV, Mills GM.  Cranial irradiation in patients with brain metastasis: a retrospective study of timing.  Radiation Medicine 17:271-271, 1999.
  39. Mills KM, Johnson DM, Middlebrook M, Burton GV.  Paclitaxel/Cremophor associated pancreatitis.  Pharmacotherapy 20:95-97, 2000.
  40. Ampil FL, Mills GM, Stucker FJ, Burton GV, Nathan CAO.  Radical combined treatment of locally extensive head and neck cancer in the elderly.  Amer J Otolaryngology 22:65-69, 2001.
  41. Nabholtz JM, Buzdar A, Pollak M, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:  Results of a North American multicenter randomized study.  J Clin Oncol 18: 3758-3767, 2000.
  42. Li BDL, Brown WA, Ampil FL, Burton GV, Yu H, McDonald JC.  Patient compliance is critical for equivalent clinical outcomes for breast cancer treated by breast conservation therapy, Ann Surg 231:883-9, 2000.
  43. Burton GV.  Chemotherapy in malignant gliomas. Seminars Neurosurg 11:373-385, 2000.
  44. Li A, Burton G, Glass J.  Breast cancer: a socioeconomic and racial comparison in Northwest Louisiana.  J La State Med Soc 153:420-425, 2001.
  45. Ampil FL, Burton GV, Mills GM, Jawahar A, Pelser R, Nanda A.  Cauda equina compression in breast cancer- incidence and treatment outcome.  Eur J Gynaec Oncol 22:257-259, 2001.
  46. Ampil FL, Mills G.M, Burton GV.  A retrospective study of metastatic lung cancer compression of the cauda equina.  Chest 120:1754-1755, 2001.
  47. Ampil FL, Burton GV, Li BD.  Routine weekly blood counts during breast irradiation for early stage cancer: are they really necessary?  Breast J 7:450-2, 2001.
  48. Ampil FL, Mills GM, Caldito G, Burton GV, Nathan CAO, Aarstad RF, Lian TF, Stucker FJ, Hardin JC.  Induction chemotherapy followed by concomitant chemoradiation-induced regression of advanced cervical lymphadenopathy in head and neck cancer as a predictor of outcome.  Otolaryng Head Neck Surg 126:602-606, 2002.
  49. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertlser, SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A.  Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post-menopausal women with advanced breast cancer progression on prior endocrine therapy: results of a North American trial.  J Clin Oncol 20:3386-3395, 2002.
  50. Ampi, FL, Caldito G, Mills GM, Burton GV, Neupane P.  Is chemoradiation as effective as surgery with postoperative radiotherapy for locally advanced (operable) head and neck cancer?  A retrospective observational study.  Radiation Medicine  20:217-219, 2002.
  51. Ampil FL, Caldito G, Li BD., Burton GV.  Supraclavicular nodal relapse of breast cancer:  Prevalence, palliation and prognosis.  Eur J Gynaec Oncol24:233-235, 2003.
  52. Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L; Trial 0020 Investigators; Trial 0021 Investigators.  Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy.  Breast Cancer Res Treat 79:207-11, 2003.
  53. Ampil FL, Mills GM, Nathan CA, Burton GV, Mansour R, Hardjasudarma M.  Positive response of advanced oropharyngeal cancer with trismus to chemoradiation.  South Med J 96:316-7, 2003.
  54. Ampil F, Mills G, Burton G, Malik A, Krishnamsetty RM.  Successful treatment of head and neck cancer involving the prevertebral fascia.  South Med J 97:1126-7, 2004.
  55. Ampil FL, Burton GV, Li BDL, Chu Q, Krishnamsetty RM, Caldito G.  Thoracic metastasis from breast cancer: a single-institution’s experience.  Eur J Gynaec Oncol 26:155-157, 2005.
  56. Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Jaeckle KA, Buckner JC.  Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. J Neurooncol 5:1-6, 2005.
  57. Alassas M, Chu Q, Burton G, Ampil F, Mizell J, Li BD.  Neoadjuvant chemotherapy in stage III breast cancer. Am Surg. 71:487-92, 2005.
  58. Wolfort RM, Li BD, Johnson LW, Turnage RH, Lilien D, Ampil F, Burton G, Chu QD.  The Role of Whole-Body Fluorine-18-FDG Positron Emission Tomography in the Detection of Recurrence in Symptomatic Patients with Stages II and III Breast Cancer. World J Surg.  30:1-6, 2006.
  59. Buckner JC, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O’Fallon JR, Ballman, KV.  Phase III trial of BCNU plus cisplatin versus BCNU alone, and standard radiation versus accelerated radiation therapy in patients with glioblastoma multiforme: NCCTG93-72-52, SWOG 9503.  J Clin Oncol. Accepted 5/2006.
  60. Von Burton GV, Rankin C, Flaherty LE, Mills GM, Borden EC, Antman K. for the Southwest Oncology Group.   Phase II Trial of Gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcomas (STS). Amer J Clinical Oncology  29:59-61, 2006.
  61. Potluri V, Lewis D, Burton GV.  Chemotherapy with taxanes in breast cancer during pregnancy: case report and review of the literature.  Clin Breast Cancer. 7:167-70, 2006.
  62.  Ampil FL, Burton GV, Hardjasudarma M, Henley T.  Breast cancer metastasis to the gasserian ganglion.
    South Med J. 99:93-4, 2006.
  63. Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Jaeckle KA, Buckner JC.  Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.
    J Neurooncol. 77:315-20, 2006.
  64. Ye G, Nathan CA, Ampil FL, Burton GV.  Squamous Cell Carcinoma of the Oral Cavity Following Breast Cancer Treatment:  A report of two cases and review of the literature.   South Med J. 99:1-2, 2006.
  65. Hussain S, Nanda A, Fowler M, Ampil FL, Burton GV.  Primary intracranial leiomyosarcoma: report of a case and review of the literature.  Sarcoma 2006:1-3, 2006.
  66. Wolfort RM, Li BD, Johnson LW, Turnage RH, Lilien D, Ampil F, Burton G, Chu QD.  The role of whole-body fluorine-18-FDG positron emission tomography in the detection of recurrence in symptomatic patients with stages II and III breast cancer.  World J Surg 30:1422-7, 2006 .
  67. Boniol S, Boyd M, Koreth R, Burton GV.  Wernicke encephalopathy complicating lymphoma therapy: case report and literature review.  South Med J 100:717-9, 2007
  68. Turturro F, Von Burton G, Friday E.  Hyperglycemia-induced thioredoxin-interacting protein expression differs in breast cancer-derived cells and regulates paclitaxel IC50.  Clin Cancer Res  15:13:3724-30, 2007.
  69. Albain KS, Green SR, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Herman CJ, Schneider DJ, Abeloff MD, Henderson IC, Norton L, Lew D, Livingston RB, Martino S, Osborne CK.  A phase II trial of adjuvant cyclophosphamide, adriamycin and 5-fluorouracil (CAF) plus sequential tamoxifen, CAF plus concurrent tamoxifen, or tamoxifen alone in postmenopausal women with node-positive, receptor-positive breast cancer: Mature outcomes from Southwest Oncology Group Study 8814 (INT-0100).  N Eng J Med.  Accepted 10/2007.
  70. Ampil F, Burton GV, Gonzalez-Toledo E, Nanda A.  Do we need whole brain irradiation in multifocal or multicentric high-grade cerebral gliomas? Review of cases and the literature.  J Neurooncol  2007 May 30; [Epub ahead of print]

 

Refereed Abstracts
1.            Burton GV, Meikle AW.  Partial adrenal insufficiency following chronic methylmercury poisoning.  Clin Res  25: 145A, 1977.
3.            Burton GV, Huang A.  Patterns of recurrence in head and neck lymphomas: Excess central nervous system recurrence.  Proc Amer Soc Clin Oncol  4:C806, 1985.
4.            Flowers J, Burton G, Cox E, Geissenger K, Leight G, McCarty K.  Monoclonal antiestrogen antibody (H222) to evaluate estrogen receptor content in fine needle aspiration biopsies. Proc Intern Acad Path, 1985.
5.            Burton G, Flowers J, Cox E, Geissenger K, Leight G, McCarty K Jr.  Monoclonal antiestrogen antibody (H222) in breast cancer:  A predictive marker of response to hormonal therapy. Breast Cancer Res Treat 6:164, 1985.
6.            Cox EB, Burton GV, Olsen GA, Vugrin D.  Response of Refractory Breast Cancer to a combination of cisplatin and etoposide.  Proc Amer Soc Clin Oncol  5:C249, 1986.
7.            Burton GV, Wolfe WG, Crocker IR, Medoff JR, Prosnitz LR.  Esophageal carcinoma:  Response to cisplatin and etoposide chemotherapy.  Proc Amer Soc Clin Oncol  5:C334, 1986.
8.            Everson RB, Carrano AV, Burton GV, Wyrobeck AJ.  Induction, accumulation, and persistence of sister chromatid exchanges and chromosomal aberrations in women treated with CMF adjuvant therapy for breast cancer.  Proc Amer Assoc Can Res 26:C247, 1986.
9.            Leight G, Cox EB, Burton GV, Brinkehouse A, Flowers JL, McCarty KS Sr, McCarty KS Jr.  Tumor asynchrony versus heterogeneity in human breast cancer.  Proceedings of International Academy of Pathology, 1986.
10.          Burton GV, Cox EB, Leight GS, Prosnitz LR, Iglehart JD, Olsen GA, Seigler HF, Hart LL.  Inflammatory breast carcinoma: Effective multimodality approach with short-term chemotherapy, surgery, and radiation therapy.  Proceedings of the Joint Annual Meeting of the Association of Head and Neck Oncologists of Great Britain, British Association of Surgical Oncology, Society of Head and Neck Surgeons, and Society of Surgical Oncology, 1987.
11.          Cox EB, Burton GV, Olsen GA, Vugrin D.  Response of refractory breast carcinoma to a combination of cisplatin and etoposide.  Proc Amer Soc Clin Oncol 6:C226, 1987.
12.          Burton GV, Grant JP, Bedrosian C, Cox E.  Cisplatin and continuous infusion 5FU chemotherapy in metastatic colon cancer. Proc Amer Soc Clin Oncol  6:C330, 1987.
13.          Green DM, Burton GV, Cox EB, Hanson D, Moore J, Oleson JR.  A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy.  Int J Rad Oncol  Biol Physics 13:(suppliment) 130, 1987.
15.          Carter P, Burton GV, Wolfe W, Crocker I, Seigler H, Prosnitz L, Crawford J.  Squamous cell carcinoma of the esophagus:  Effective multimodal therapy. Proc Amer Soc Clin Oncology 8:404, 1989.
16.          Burton GV, Wolfe W, Carter P, et al.  Adenocarcinoma of the gastroesophageal junction: Effective multimodal therapy.  Proc Amer Soc Clin Oncology 8:473, 1989.
17.          Berglund E, Burton G, Bordelon T, Mills G, Blanchet P, Morris D, Glass J, Nichols G, Hertler A.  Cisplatin, etoposide, and 5-fluorouracil combination chemotherapy in refractory metastatic breast carcinoma. Breast Cancer Research and Treatment 14:143. 1989.
18.          Burton G, Huang A, Lazarus H, Moore J, House KW, Finn AL.  A double-blind randomized comparison of three doses of IV ondansetron for prevention of emesis induced by multi-day cisplatin therapy.  Proc Amer Soc Clin Oncology 9:328, 1990.
19.          Gruber M, Prados M, Russell C, Hochberg F, Cook P, Weissman D, Evans R, Burton G, Allen D, Brannon R.  Phase I/II study of Fluosol/O2 in combination with BCNU in malignant glioma.  Proc Amer Assoc Cancer Res 31:190, 1990.
20.          Burton GV, Mills GM, Nichols G, Blanchet P.  Ifosfamide and carboplatin combination chemotherapy in advanced breast cancer. Breast Cancer Res Treat 19:143A, 1991.
21.          Burton GV, Schwalke MA, Bahrassa F, Mills GM, Bounds WE.  Stage IIIB locally advanced breast cancer: Alternating non-cross resistant preoperative treatment with cisplatin and doxorubicin based regimens. Proceedings 4th International Conference Adjuvant Therapy of Breast Cancer 4:64, 1992.
22.          Li A, Burton G, Glass J.  Breast cancer socioeconomic and racial comparison between hospital populations. Clinical Research 41:235A, 1993.
23.          Payne DK, Barnes L, Holladay R, Owens MW, George RB, Burton GV, etal.  Indomethacin decreases pleural fluid formation in patients with adenocarcinoma-induced malignant pleural effusions.  Chest 103:299S, 1993.
24.          Hebert C, Martin A, Schwalke M, Davis T, Burton G.  Literacy and breast cancer. Clinical Research 41:802A, 1994.
25.          Vo P, Davis T, Li A, Burton G.  Literacy and cancer. Proc Amer Assoc Cancer Res 35:287, 1994.
26.          Hebert C, Martin A, Schwalke M, Davis T, Burton G.  Literacy and breast cancer. Breast Canncer Res Treat 32:228A (suppliment), 1994.
27.          Steiner S, Li A, Abreo, F, Schwalke M, Burton G.  Racial differences in frequency of breast cancer ductal carcinoma in-situ. J Investigative Medicine 43:235A (suppliment), 1995.
28.          Burton GV, Weinberger BB, Mills GM.  Ifosfamide and platinol combination chemotherapy in advanced breast cancer: cisplatin is superior to carboplatin.  Procceedings of Sixth International Congress on Anti-Cancer Treatment, 1996.
29.          Weinberger BB, Lerchie S, Loper K, Dayton MA, Blanchard RF, Holcombe RF, Burton GV.  Phase I/II trial of taxol as part of a double (sequential) high dose chemotherapy program for patients with previously untreated metastatic breast cancer.  Proc Amer Soc Clin Oncol  1997.
30.          Demouy J, Person K, Ampil F, Burton GV.  Racial differences in breast fibrosis after breast conservation therapy for primary breast cancer.  Proc Amer Soc Cancer Research 38:247, 1997.
31.          Demouy J, Person K, Burton GV.  Factors associated with increased fibrosis of the breast in breast cancer patients following lumpectomy and radiation therapy. J La State Med Soc 149:427, 1997.
32.          Cain MS, Burton GV, Holcombe RF.  Fatal leukoencephalopathy in a patient with non-Hodgkin’s lymphoma treated with CHOP chemotherapy.  J Investigative Medicine, 45:10A 1997.
33.          Ampil F, Burton G, Li B, Minnard E, Abreo F, Person K, Ethridge L, Mills G, Chin H.  Is the timing of radiotherapy after breast conservation surgery for early stage breast cancer important?  European Journal of Cancer, 34:S61  1998 (suppliment 5).
34.          Mills GM, Burton G, Campbell L, Ampil F.  Treatment of inoperable head and neck cancer in the elderly.  Ann Oncol 9:124, 1998 (suppliment 3).
35.          Ampil FL, Sadasivan KK, Burton GV, Mills GM.,  Palliative management of metastasis in weight-bearing ling bones. Proc Amer Soc Cancer Research 40:555-556A, 1999.
36.          Brown WA, Minnard EA, Hedden W, Ampil F, Burton G, Li BDL.  Breast conservation therapy: A difficult management decision. Breast Cancer Research and Treatment 50:246A, 1998.
37.          Brown WA, Minnard EA, Hedden W, Ampil F, Burton G, Li BDL.  Breast conservation therapy: A difficult management decision. Breast Cancer Research and Treatment 50:246A, 1998.
38.          Denduluri N, Carrico JC, Person K, Burton GV.  Factors influencing breast cancer patients’ perception of risk recurrence. Breast Cancer Research and Treatment 50:307A, 1998.
39.          Ampil F, Burton G, Li B et al.  Is the timing of radiotherapy after breast conservation surgery for early stage breast cancer important?  European J Cancer 34:61A, 1998.
40.          Ampil FL, Burton GV, Li BDL, Mills GM, Patil R.  The omission of postoperative regional lymphatic irradiation in early stage breast cancer: harmful or not?  Proceedings of the 7th Biannual International Gynecologic Oncology Society Meeting 7:59-62, 1999.
41.          Ampil FL, SadasivanKK, Burton GV, Mills GM.  Palliative management of metastasis in weight-bearing long bones.  Proceedings 90th Annual Meeting American Association Cancer Research 40:555, 1999.
42.          Mills GM, Ampil FL, Ratts V, Burton G. Multimodality therapy of esophageal cancer.  Proceedings 1st International Chicago Symposium on Malignancies of the Chest, 1999.
43.          Brown WA, Minnard EA, Ampil F, Burton G, Li BDL.  Breast conservation therapy in an indigent population: a difficult management decision.  Proceedings Southeastern Surg 67:19, 1999.
44.          Brown WA, Hedden WJ, Burton G, Ampil F, Li BDL.  Neoadjuvant chemoradiation therapy for extremity sarcoma.  Proceed LACS 9, 1999.
45.          Li BDL, Brown WA, Ampil FL, Burton GV, Yu H.  Patient compliance is critical for equivalent clinical outcomes for breast cancer treated by breast conservation therapy.  Proceedings of the Southern Surgical Society, 1999.
46.          Burton GV, Ampil F, Mills,G, Nathan C, Gammage C.  Nasopharyngeal cancer: multidisciplinary therapy with cisplatin, 5-fluorouracil, etoposide and radiotherapy.  Proceedings of the 10th International Congress on Anti-Cancer Treatment 10:118, 2000.
47.          Mills GM, Ratts V, Yu H, Ampil F, Burton GV, Li N.  Combined modality therapy of esophageal cancer. Proceedings of the 10th International Congress on Anti-Cancer Treatment 10:246, 2000.
48.          Carrico J, Person K, Shi R, Burton E, Richard M, Li B, Ampil F, Patil R, Burton G.  Lymphedema in breast cancer patients.  Supportive Care in Cancer 8:248A, 2000.
49.          Abdel-Rahman H, Mansour R, Shi R, Mills G, Burton GV, Berkel J, Patil R.   Metastatic cancer of unknown primary site: identification of favorable clinical subsets.   Proceedings American Society Clinical Oncology 19:579a, 2000.
50.          Chaudry S, Abdel-Rahman HA, Patil R, Mansour R, Mills G, Burton G.  Prospective Phase II Study of weekly cisplatin-gemcitabine in refractory breast cancer. Proceedings 36th American Society Clinical Oncology 19:111a, 2000.
51.          Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gentler S, May JT, Burton G, Webster A, Morris C, Dimery I, Elledge R, Buzdar A.  Faslodex (ICI 182,780) shows longer duration of response compared with arimidex (anastrozole) in post-menopausal women with advanced breast cancer.  Preliminary results of a phase III North American trial.  Program Proceedings 23rd Annual San Antonio Breast Cancer Symposium 2000 (Late Program Addition).  Breast Cancer Research and Treatment 52, 2001.
52.          Buckner JC, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Hawkins RB, Scheithauer BW, O’Fallon JR.  Phase III trial of BCNU plus cisplatin (CDDP) versus BCNU alone, and standard radiation versus accelerated radiation therapy in glioblastoma patients: NCCTG/SWOG results. Proceedings 37th American Society Clinical Oncology 20:51a, 2001.
53.          Neupane PC, Patil R, Mansour R, Mills G, Burton GV.  PhaseI/II study of weekly cisplatin and docetaxel as first line chemotherapy in metastatic carcinoma of the breast. Proceedings 37th American Society Clinical Oncology 20:1922a, 2001.
54.          Ampil FL, Mills GM, Burton GV, Nathan CA, Caldito G.  Induction chemotherapy followed by chemoradiation for advanced nodal disease in head and neck cancer.  International Journal of Cancer (supplement 13):  Proceedings of the 18th UICC International Cancer Congress 18:431, 2002.
55.          Saleh M, Irwin D, Burton G, Hargis J, Chitambar C, Jones CM, Shapiro CL, Oliver JW, Holmlund JT, Dorr FA.  Phase 2 Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Weekly Paclitaxel in the Treatment of Patients with Metastatic Breast Cancer. Proceedings 39th American Society Clinical Oncology 22:207, 2003.
56.          Burton GV, Rankin C, Flaherty LE, Mills GM, Borden EC, Antman K. for the Southwest Oncology Group.   Phase II Trial of Gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcomas (STS).  Proceedings 39th American Society Clinical Oncology 22:820, 2003.
57.          Chu Q, Turnage R, Burton G, Ampil F, McDonald J, Li DB L.  Neoadjuvant chemotherapy attenuates the overexpression of eIF4E in patients with breast carcinomas.  Second Annual Proceedings of the AACR International Conference on Frontiers in Cancer Prevention Research 2:86-87, 2003.
58.          P Reddy, A Jawahar, VSSV Prasad, R Mansour, F Ampil, G Burton, A Nanda. Gamma knife radiosurgery for metastatic brain tumors: A preliminary experience. Presented at the 2002, 7th Annual meeting of Society for Neuro-Oncology, San Diego (11/2002).
59.          P Reddy, G Burton VSSV Prasad, R Mansour, F Ampil, A Nanda. Glioblastoma multiforme in elderly patients:  Impact of chemotherapy on survival. Presented at the 2002, 7th Annual meeting of Society for Neuro-Oncology, San Diego (11/2002).
60.          Albain KS, Green SR, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Herman CJ, Schneider DJ, Abeloff MD, Henderson IC, Norton L, Lew D, Livingston RB, Martino S, Osborne CK.  A phase II trial of adjuvant cyclophosphamide, adriamycin and 5-fluorouracil (CAF) plus sequential tamoxifen, CAF plus concurrent tamoxifen, or tamoxifen alone in postmenopausal women with node-positive, receptor-positive breast cancer: Mature outcomes from Southwest Oncology Group Study 8814 (INT-0100).  Breast Cancer Research and Treatment 88:Supplimental abstract. 2004.
61.          C. G. Hargon, G. Burton, B. Li, F. Ampil, D. Lillian.  6FDG PET scan evaluation of suspicious breast lesions developing after breast conservation therapy for breast cancer.  Proceedings American Society Clinical Oncology 23:30, 2004.